المؤلفون: Korkmaz, Pınar, Demirtürk, Neşe, Aydın, Gule, Çeken, Sabahat, Aygen, Bilgehan, Toka, Onur, Gündoğdu, Kıymet, Çelikbaş, Aysel Kocagül, İnan, Dilara, Kuruüzüm, Ziya, Kutsoylu, Oya Özlem Eren, Batırel, Ayşe, Sırmatel, Fatma, Ersöz, Gülden, Hakyemez, İsmail Necati, Aşçı, Zerrin, Yeşilbağ, Zuhal, Sönmezer, Meliha Çağla, Tülek, Necla, Örmen, Bahar, Karadağ, Fatma Yılmaz, Yörük, Gülşen, Türker, Nesrin, Özkaya, Hacer Deniz, Kalkan, İrem Akdemir, Süer, Hüseyin Kaya, Tekin, Süda, Saltoğlu, Neşe, Şener, Alper, Yenilmez, Ercan, Çetinkaya, Rıza Aytaç, Özel, Selcan Arslan, Ayaz, Celal, Karagöz, Ergenekon, Aydın, Mehtap, Acar, Ali, Arslan, Eyüp, Ceylan, Mehmet Reşat, Demir, Nazlım Aktuğ, Çaylak, Selmin Dirgen, Günal, Özgür, Solay, Aslı Haykır, Öztürk, Sinan, Ural, Onur, Sümer, Şua, Kadanalı, Ayten, Altıparmak, Vuslat Ecem Güneş, Akhan, Sıla, Sayan, Murat, Köse, Şükran

المساهمون: Selçuk Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, orcid:0000-0001-5035-5895, orcid:0000-0002-6186-2494, orcid:0000-0002-7635-8848, orcid:0000-0002-3679-0978, orcid:0000-0002-7598-6578, orcid:0000-0002-4025-4537, orcid:0000-0002-3366-9136, orcid:0000-0002-7448-5210, orcid:0000-0002-7551-6728, orcid:0000-0002-1095-8226, orcid:0000-0003-3814-0474, orcid:0000-0002-6005-636X, orcid:0000-0003-0442-5981, orcid:0000-0003-2836-3586, orcid:0000-0001-6133-9604, orcid:0000-0001-9461-3075, orcid:0000-0002-7210-1084, orcid:0000-0002-3952-4982, orcid:0000-0003-0895-2420, orcid:0000-0003-4657-5291, orcid:0000-0002-0357-5884, orcid:0000-0003-3329-0545, orcid:0000-0002-5212-9629, orcid:0000-0001-5136-9148, orcid:0000-0002-2565-3425, orcid:0000-0001-9419-8713, orcid:0000-0003-4239-9585, orcid:0000-0003-2774-8601, orcid:0000-0002-1145-8856, orcid:0000-0002-5676-9527, orcid:0000-0002-2844-5410, /0000-0002-9060-1090, orcid:0000-0003-4044-9366, orcid:0000-0003-2008-5112, orcid:0000-0002-5490-465X, orcid:0000-0001-8063-4836, orcid:0000-0002-4703-0827, orcid:0000-0002-7771-9342, orcid:0000-0002-7744-4123, orcid:0000-0002-1326-9776, orcid:0000-0003-4231-3753, orcid:0000-0003-1355-7572, orcid:0000-0003-3508-7516, orcid:0000-0002-3176-2126, orcid:0000-0001-7438-9205, orcid:0000-0002-2540-2060, orcid:0000-0002-4374-7193, orcid:0000-0002-4228-1213, Demir, Nazlım Aktuğ, Ural, Onur, Sümer, Şua

مصطلحات موضوعية: Hepatitis B, immunosuppression, reactivation

الوصف: WOS: 000481718600008 ; Objective: This study aimed to evaluate the awareness and knowledge levels of all physicians administering immunosuppressive treatment concerning hepatitis B virus (HBV) reactivation, and draw attention to the importance of the subject through evaluation. Methods: The study was carried out by infectious diseases and clinical microbiology specialists in 37 health centers, and it was performed in Turkey between January and March 2017. All specialists providing a written consent and working in the departments of Medical Oncology, Hematology, Dermatology and Venereology, Physical Medicine and Rehabilitation, and Rheumatology of each study center were included in the study. Results: A total of 430 physicians participated in the study. Their mean age was 39.87 +/- 7.42 years, and 47.9% of them were males. During their career, 39.3% of these physicians had encountered patients developing HBV reactivation while receiving immunosuppressive treatment. The rate of encountering patients who died due to HBV reactivation was 6.5%. 97% of physicians who participated, considered the risk of HBV reactivation to be important. 70.2% of physicians stated that guidelines related to HBV reactivation and antiviral treatment for these patients were discussed in the congresses they participated, regarding their specialties. The rate of performing hepatitis screening among physicians whose patients developed HBV reactivation was statistically significantly higher than those physicians who had no patients with HBV reactivation (p<0.05). Physicians who used the guidelines related to HBV reactivation in their specialties performed screening for the HBV infection much more often than physicians who did not use the guidelines (p=0.002). Conclusions: According to the results obtained in our study, the rates of conducting screening and awareness of HBV reactivation among physicians administering immunosuppressive treatment were higher compared with similar studies; however, their awareness that HBV DNA and anti-HBc ...

العلاقة: KLIMIK JOURNAL; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Korkmaz, P., Demirtürk, N., Aydın, G., Çeken, S., Aygen, B., Toka, O., Gündoğdu, K., Çelikbaş, A. K., İnan, D., Kuruüzüm, Z., Kutsoylu, O. Ö. E., Batırel, A., Sırmatel, F., Ersöz, G., Hakyemez, İ. N., Aşçı, Z., Yeşilbağ, Z., Sönmezer, M. Ç., Tülek, N., Örmen, B., Karadağ, F. Y., Yörük, G., Türker, N., Özkaya, H. D., Kalkan, İ. A., Süer, H. K., Tekin, S., Saltoğlu, N., Şener, A., Yenilmez, E., Çetinkaya, R. A., Özel, S. A., Ayaz, C., Karagöz, E., Aydın, M., Acar, A., Arslan, E., Ceylan, M. R., Demir, N. A., Çaylak, S. D., Günal, Ö., Solay, A. H., Öztürk, S., Ural, O., Sümer, Ş., Kadanalı, A., Altıparmak, V. E. G., Akhan, S., Sayan, M., Köse, Ş. (2019). Awareness of Hepatitis B Virus Reactivation Among Physicians Administering Immunosuppressive Treatment and Related Clinical Practices. Klimik Journal, 32(2), 146-153.; https://dx.doi.org/10.5152/kd.2019.33Test; https://hdl.handle.net/20.500.12395/37522Test; 32; 146; 153

الإتاحة: https://doi.org/20.500.12395/37522Test
https://doi.org/10.5152/kd.2019.33Test
https://hdl.handle.net/20.500.12395/37522Test

المؤلفون: Korkmaz, Pınar, Demirtürk, Neşe, Aydın, Güle Ç., Çeken, Sabahat, Aygen, Bilgehan, Toka, Onur, Gündoğdu, Kıymet, Çelikbaş, Aysel Kocagül, İnan, Dilara, Kuruüzüm, Ziya, Kutsoylu, Oya Özlem Eren, Batırel, Ayşe, Sırmatel, Fatma, Ersöz, Gülden Munis, Hakyemez, İsmail Necati, Aşçı, Zerrin, Yeşilbaǧ, Zuhal, Sönmezer, Meliha Çaǧla, Tulek, N., Örmen, Bahar Kopraman, Karadağ, Fatma Yılmaz, Yörük, Gülşen, Türker, Nesrin Akbaş, Özkaya, Hacer Deniz, Kalkan, İrem Akdemir, Süer, Hüseyin Kaya, Tekin, Süda, Saltoǧlu, Neşe, Şener, Alper, Yenilmez, Ercan, Çetinkaya, Rıza Aytaç, Özel, Selcan Arslan, Ayaz, Celal, Karagöz, Ergenekon, Aydın, Mehtap, Acar, Ali, Arslan, Eyüp, Ceylan, Mehmet Reşat, Demir, Nazlım Aktuǧ, Çaylak, Selmin Dirgen, Günal, Özgür, Solay, Aslı Haykır, Öztürk, Sinan, Ural, Önur, Sümer, Şua, Kadanalı, Ayten, Altıparmak, Vuslat Ecem Güneş, Akhan, Sıla Çetin, Sayan, Murat, Köse, Şükran

مصطلحات موضوعية: Hepatitis B, Immunosuppression, Reactivation, Hepatit B, İmmünosüpresyon, Reaktivasyon

الوصف: Objective: This study aimed to evaluate the awareness and knowledge levels of all physicians administering immunosuppressive treatment concerning hepatitis B virus (HBV) reactivation, and draw attention to the importance of the subject through evaluation. Methods: The study was carried out by infectious diseases and clinical microbiology specialists in 37 health centers, and it was performed in Turkey between January and March 2017. All specialists providing a written consent and working in the departments of Medical Oncology, Hematology, Dermatology and Venereology, Physical Medicine and Rehabilitation, and Rheumatology of each study center were included in the study. Results: A total of 430 physicians participated in the study. Their mean age was 39.87±7.42 years, and 47.9% of them were males. During their career, 39.3% of these physicians had encountered patients developing HBV reactivation while receiving immunosuppressive treatment. The rate of encountering patients who died due to HBV reactivation was 6.5%. 97% of physicians who participated, considered the risk of HBV reactivation to be important. 70.2% of physicians stated that guidelines related to HBV reactivation and antiviral treatment for these patients were discussed in the congresses they participated, regarding their specialties. The rate of performing hepatitis screening among physicians whose patients developed HBV reactivation was statistically significantly higher than those physicians who had no patients with HBV reactivation (p<0.05). Physicians who used the guidelines related to HBV reactivation in their specialties performed screening for the HBV infection much more often than physicians who did not use the guidelines (p=0.002). Conclusions: According to the results obtained in our study, the rates of conducting screening and awareness of HBV reactivation among physicians administering immunosuppressive treatment were higher compared with similar studies; however, their awareness that HBV DNA and anti-HBc should be utilized much more ...

وصف الملف: application/pdf

العلاقة: Klimik Dergisi; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Korkmaz, P., Demirtürk, N., Aydın, G. Ç., Çeken, S., Aygen, B., Toka, O. ve diğerleri. (2019). İmmünosüpresif tedavi veren hekimlerin hepatit b virusu reaktivasyonuyla ilgili farkındalıklarının ve klinik pratiklerinin değerlendirilmesi. Klimik Dergisi, 32(2), 146-153.; https://www.klimikdergisi.org/en/2021/01/05/awareness-of-hepatitis-b-virus-reactivation-among-physicians-administering-immunosuppressive-treatment-and-related-clinical-practicesTest/; https://hdl.handle.net/11468/7534Test; 32; 146; 153; WOS:000481718600008; 2-s2.0-85070991417; N/A

الإتاحة: https://doi.org/10.5152/kd.2019.33Test
https://hdl.handle.net/11468/7534Test
https://www.klimikdergisi.org/en/2021/01/05/awareness-of-hepatitis-b-virus-reactivation-among-physicians-administering-immunosuppressive-treatment-and-related-clinical-practicesTest/

المؤلفون: Guclu, Ertugrul, Tuna, Nazan, Karabay, Oguz, Akhan, Sila, Bodur, Hurrem, Ceylan, Bahadir, Tutuncu, Ediz

المساهمون: OMÜ

مصطلحات موضوعية: hepatitis B, interferon, sustained virological response, viral load

الوصف: Geyik, Mehmet Faruk/0000-0002-0906-0902; demirdal, tuna/0000-0002-9046-5666; KARABAY, OGUZ/0000-0003-1514-1685; Karabay, Oguz/0000-0003-0502-432X; Gunduz, Alper/0000-0001-9154-844X ; WOS: 000352106600012 ; PubMed: 25500658 ; Introduction: Although pegylated interferons (pegIFNs) alpha-2a and alpha-2b have been used in chronic hepatitis B (CHB) treatment for many years, there are few studies concerning predictors of sustained virologic response (SVR) to pegIFN therapy. In this study, we aimed to investigate the predictors of response to pegIFN treatment in cases with HBeAg-negative CHB infection. Methodology: Seventeen tertiary care hospitals in Turkey were included in this study. Data from consecutively treated HBeAg-negative CHB patients, who received either pegIFN alpha-2a or alpha-2b, were collected retrospectively. SVR is defined as an HBV DNA concentration of less than 2,000 IU/mL six months after the completion of therapy Results: SVR was achieved in 40 (25%) of the 160 HBeAg-negative CHB patients. Viral loads in patients with SVR were lower compared to those with no SVR, beginning in the third month of treatment (p < 0.05). The number of cases with a decline of 1 log(10) IU/mL in viral load after the first month of treatment and with a serum HBV DNA level under 2,000 IU/mL after the third month of treatment was higher in cases with SVR (p < 0.05). The number of patients who had undetectable HBV DNA levels at week 48 among responders was significantly greater than among post-treatment virological relapsers (p < 0.05). Conclusions: Detection of a 1 log(10) decline in serum HBV DNA level at the first month of treatment and a serum HBV DNA level < 2000 IU/mL at the third month of therapy may be predictors of SVR.

العلاقة: Journal of Infection in Developing Countries; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.3855/jidc.4953Test; https://hdl.handle.net/20.500.12712/14835Test; 12; 1601; 1608

الإتاحة: https://doi.org/20.500.12712/14835Test
https://doi.org/10.3855/jidc.4953Test
https://hdl.handle.net/20.500.12712/14835Test

المؤلفون: Koruk, Süda Tekin, Batirel, Ayşe, Köse, Şükran, Akhan, Sıla Çetin, Aygen, Bilgehan, Sırmatel, Fatma

المساهمون: BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, orcid:0000-0002-2540-2060, orcid:0000-0002-7598-6578, orcid:0000-0003-0442-5981, Sırmatel, Fatma

مصطلحات موضوعية: Antiviral Therapy, Hepatitis B, Perinatal Transmission, Pregnancy

الوصف: WOS:000368020900002 ; PubMed: 26369498 ; Aim: The aim of the present study was to assess the potential risk of hepatitis B virus (HBV) vertical transmission among Turkish parturient women and to evaluate the efficacy and safety of antiviral agents. Material and Methods: Data were collected retrospectively from 114 HBV-infected pregnant women and their infants in eight health institutions in Turkey. Results: The baseline characteristics of the women were: mean age, 28.3 +/- 5.2 years; alanine aminotransferase, 57.4 +/- 139.0 U/L; aspartate aminotransferase, 56.6 +/- 150.0 U/L; and HBV DNA, 8.3 x 10(7) +/- 2.6 x 10(8) copies/mL. Family history of HBV infection was detected in 53.5% (n = 61). In total, 60 (52.6%) pregnant women received tenofovir (60.0%), lamivudine (33.3%) or telbivudine (6.7%) therapy at the median gestational age of 22.2 +/- 8.5 (1-36) weeks. All infants were vaccinated and hepatitis B immune globulin was administered, with 81 of them (71.1%) available for follow-up. After completion of HBV vaccination course, 71 (87.7%) infants had protective anti-HBs levels, three (3.7%) were hepatitis B surface antigen-positive, and seven (8.6%) were hepatitis B surface antigen-negative with nonprotective anti-HBs levels. Five of the infants had low gestational birthweight but no other birth defects were observed. Conclusion: According to our results, viral load may not be the only effecting factor for transmission of HBV to children of infected mothers. Pregnant women with high viral load should be followed-up closely during pregnancy. They should begin to take tenofovir or telbivudine, which are category B drugs for pregnancy, at the beginning of the third trimester at the latest. We need new treatment strategies; and close follow-up of mothers and children is another important issue.

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Journal Of Obstetrics And Gynaecology Research; https://doi.org/10.1111/jog.12821Test; https://hdl.handle.net/20.500.12491/8130Test; 41; 12; 1870; 1876

الإتاحة: https://doi.org/20.500.12491/8130Test
https://doi.org/10.1111/jog.12821Test
https://hdl.handle.net/20.500.12491/8130Test

المؤلفون: Tekin Koruk, Suda, Batirel, Ayse, Kose, Sukran, Cetin Akhan, Sila, Aygen, Bilgehan, Tulek, Necla, Hatipoglu, Çigdem, Bulut, Cemal, Yıldız, Orhan, Sacligil, Cahide, Sirmatel, Fatma, Altunok, Elif

المصدر: Journal of Obstetrics & Gynaecology Research; Dec2015, Vol. 41 Issue 12, p1870-1876, 7p, 3 Charts

مصطلحات موضوعية: ANTIVIRAL agents, LAMIVUDINE, TENOFOVIR, HUMAN abnormalities, ANTIGENS, ASPARTATE aminotransferase, BIRTH weight, INFECTIOUS disease transmission, DNA, GESTATIONAL age, HEPATITIS B, HEPATITIS B vaccines, PATIENT aftercare, IMMUNOGLOBULINS, THIRD trimester of pregnancy, VIRAL antibodies, WOMEN, VIRAL load, ALANINE aminotransferase, TREATMENT effectiveness, FAMILY history (Medicine), DESCRIPTIVE statistics, DISEASE risk factors, THERAPEUTICS

مصطلحات جغرافية: TURKEY

مستخلص: Aim: The aimof the present studywas to assess the potential risk of hepatitis B virus (HBV) vertical transmission among Turkish parturient women and to evaluate the efficacy and safety of antiviral agents. Material and Methods: Data were collected retrospectively from 114 HBV-infected pregnant women and their infants in eight health institutions in Turkey. Results: The baseline characteristics of the women were: mean age, 28.3±5.2 years; alanine aminotransferase, 57.4±139.0 U/L; aspartate aminotransferase, 56.6±150.0 U/L; and HBV DNA, 8.3× 107±2.6×108 copies/mL. Family history of HBV infection was detected in 53.5% (n= 61). In total, 60 (52.6%) pregnant women received tenofovir (60.0%), lamivudine (33.3%) or telbivudine (6.7%) therapy at the median gestational age of 22.2±8.5 (1-36) weeks. All infants were vaccinated and hepatitis B immune globulin was administered, with 81 of them (71.1%) available for follow-up. After completion of HBV vaccination course, 71 (87.7%) infants had protective anti-HBs levels, three (3.7%) were hepatitis B surface antigen-positive, and seven (8.6%) were hepatitis B surface antigen-negative with nonprotective anti-HBs levels. Five of the infants had low gestational birthweight but no other birth defects were observed. Conclusion: According to our results, viral load may not be the only effecting factor for transmission of HBV to children of infected mothers. Pregnant women with high viral load should be followed-up closely during pregnancy. They should begin to take tenofovir or telbivudine, which are category B drugs for pregnancy, at the beginning of the third trimester at the latest. We need newtreatment strategies; and close follow-up ofmothers and children is another important issue. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Obstetrics & Gynaecology Research is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Asan, Ali¹ draasan@yahoo.com, Sayan, Murat^2,3, Akhan, Sila⁴, Koruk, Suda Tekin⁵, Aygen, Bilgehan⁶, Sirmatel, Fatma⁷, Eraksoy, Haluk⁸, Tuna, Nazan⁹, Köse, Sukran¹⁰, Kaya, Ali¹¹, Tulek, Necla Eren¹², Demir, Nazlim Aktug¹³, Mistik, Resit¹⁴, Ormen, Bahar¹⁵, Korkmaz, Fatime¹⁶, Yildirmak, Taner¹⁷, Ural, Onur¹³, Aydin, Mehtap¹⁸, Turgut, Huseyin¹⁹, Gunal, Ozgur²⁰

المصدر: Hepatitis Monthly. Jan2018, Vol. 18 Issue 1, p1-9. 9p. 4 Charts.

مصطلحات موضوعية: *CHRONIC hepatitis B, *ANTIGENS, *ANTIVIRAL agents, *DNA, *DRUG resistance, *HEPATITIS B, *GENETIC mutation, *POLYMERASE chain reaction, *DATA analysis software, *SEQUENCE analysis, *DIAGNOSIS

مصطلحات جغرافية: TURKEY

مستخلص: Background: Hepatitis B virus (HBV) has a high mutation rate due to its unusual replication strategy leading to the production of a large number of virions with single and double mutations. The mutations, in turn, are associated with the development of drug resistance to nucleos(t)ide analogs (NUCs) in patients before and during NUCs therapy. Objectives: The current study aimed at investigating the molecular characterization of HBV in Turkish patients with chronic hepatitis B (CHB) infection. Methods: Polymerase chain reaction (PCR) amplificationanddirect sequencing procedures were used to analyze mutations. The detected drug resistance mutations were divided into the nucleos(t)ide analogs primary, partial, and compensatory resistance groups. The amino acid substitutions of hepatitis B surface antigen (HBsAg) were categorized into antiviral drug - associated potential vaccine - escape mutations (ADAPVEMs) and typical HBsAg amino acid substitutions, which included hepatitis B hyperimmunoglobulin (HBIg) - selected escape mutation, vaccine escape mutation, hepatitis B misdiagnosis, and immune - selected amino acid substitutions. Results: The number of patients included in the study was 528 out of which 271 (51.3%) were treatment - naive and 351 (66.3%) were hepatitis B e antigen (HBeAg) - negative. Moreover, 325 (61.6%) were males with a mean age of 38 years (range: 18 - 69). Primary, partial, and compensatory resistance to NUCs was reported in 174 (32.9%) patients. Six different ADAPVEM motifs were determined in both treatment - naive and treatment - experienced patients, namely, sF161L/rtI169X, sE164D/rtV173L, sL172L/rtA181T, sL173F/rtA181V, sS195M/rtM204V, and sS196L/rtM204I. The prevalence of ADAPVEMs and typical HBsAg escape mutations was 5.3% (n = 28) and 34.8% (n = 184), respectively. Conclusions: The analysis of drug resistance should constitute a fundamental part of the follow - up period of patients with CHB undergone treatment with NUCs. The surveillance of development of drug resistance mutations, while receiving treatment for hepatitis B is of paramount importance to monitor and control the emerging resistance. [ABSTRACT FROM AUTHOR]

المساهمون: Koruk, Süda Tekin, Korkmaz, Pınar, Demirtürk, Neşe, Aydın, Güle, Çeken, Sabahat, Aygen, Bilgehan, Toka, Onur, Gündoğdu, Kıymet, Kocagül-Çelikbaş, Aysel, İnan, Dilara, Kuruüzüm, Ziya, Eren-Kutsoylu, Oya Özlem, Batırel, Ayşe, Sırmatel, Fatma, Ersöz, Gülden, Hakyemez, İsmail Necati, Aşçı, Zerrin, Yeşilbağ Zuhal, Sönmezer, Meliha Çağla, Tülek, Necla, Örmen, Bahar, Yılmaz-Karadağ, Fatma, Yörük, Gülşen, Türker, Nesrin, Özkaya, Hacer Deniz, Akdemir-Kalkan, İrem, Süer, Hüseyin Kaya, Saltoğlu, Neşe, Şener, Alper, Yenilmez, Ercan, Çetinkaya, Rıza Aytaç, Arslan-Özel, Selcan, Ayaz, Celal, Karagöz, Ergenekon, Aydın, Mehtap, Acar, Ali, Arslan, Eyüp, Ceylan, Mehmet Reşat, Aktuğ-Demir, Nazlım, Dirgen-Çaylak, Selmin, Günal, Özgür, Haykır-Solay, Aslı, Öztürk, Sinan, Ural, Onur, Sümer, Süa, Kadanalı, Ayten, Güneş-Altıparmak, Vuslat Ecem, Akhan, Sıla, Sayan, Murat, Köse, Şükran, Koç University Hospital

المصدر: Klimik Journal / Klimik Dergisi

مصطلحات موضوعية: Medicine, general and internal, Microbiology, Hepatitis B, Immunosuppression, Reactivation

الوصف: Objective: this study aimed to evaluate the awareness and knowledge levels of all physicians administering immunosuppressive treatment concerning hepatitis B virus (HBV) reactivation, and draw attention to the importance of the subject through evaluation. Methods: the study was carried out by infectious diseases and clinical microbiology specialists in 37 health centers, and it was performed in Turkey between January and March 2017. All specialists providing a written consent and working in the departments of Medical Oncology, Hematology, Dermatology and Venereology, Physical Medicine and Rehabilitation, and Rheumatology of each study center were included in the study. Results: a total of 430 physicians participated in the study. Their mean age was 39.87 +/- 7.42 years, and 47.9% of them were males. During their career, 39.3% of these physicians had encountered patients developing HBV reactivation while receiving immunosuppressive treatment. The rate of encountering patients who died due to HBV reactivation was 6.5%. 97% of physicians who participated, considered the risk of HBV reactivation to be important. 70.2% of physicians stated that guidelines related to HBV reactivation and antiviral treatment for these patients were discussed in the congresses they participated, regarding their specialties. The rate of performing hepatitis screening among physicians whose patients developed HBV reactivation was statistically significantly higher than those physicians who had no patients with HBV reactivation (p<0.05). Physicians who used the guidelines related to HBV reactivation in their specialties performed screening for the HBV infection much more often than physicians who did not use the guidelines (p=0.002). Conclusions: according to the results obtained in our study, the rates of conducting screening and awareness of HBV reactivation among physicians administering immunosuppressive treatment were higher compared with similar studies; however, their awareness that HBV DNA and anti-HBc should be utilized much ...

وصف الملف: pdf

العلاقة: Publisher version; Koç University Institutional Repository; Korkmaz, Pinar, Nese Demirturk, Gule Aydin, Sabahat Ceken, Bilgehan Aygen, Onur Toka, Kiymet Gundogdu, Celikbas A. Kocagul, Dilara Inan, Ziya Kuruuzum, Kutsoylu O. O. Eren, Ayse Batirel, Fatma Sirmatel, Gulden Ersoz, Ismail N. Hakyemez, Zerrin Asci, Zuhal Yesilbag, Meliha C. Sonmezer, Necla Tulek, Bahar Ormen, Karadag F. Yilmaz, Gulsen Yoruk, Nesrin Turker, Hacer D. Ozkaya, Kalkan I. Akdemir, Huseyin K. Suer, Suda Tekin, Nese Saltoglu, Alper Sener, Ercan Yenilmez, Riza A. Cetinkaya, Ozel S. Arslan, Celal Ayaz, Ergenekon Karagoz, Mehtap Aydin, Ali Acar, Eyup Arslan, Mehmet R. Ceylan, Demir N. Aktug, Caylak S. Dirgen, Ozgur Gunal, Solay A. Haykir, Sinan Ozturk, Onur Ural, Sua Sumer, Ayten Kadanali, Altiparmak V. E. Gunes, Sila Akhan, Murat Sayan, and Sukran Kose. "Awareness of Hepatitis B Virus Reactivation Among Physicians Administering Immunosuppressive Treatment and Related Clinical Practices." Klimik Dergisi/klimik Journal. 32.2 (2019): 146-153.; https://dx.doi.org/10.5152/kd.2019.33Test; IR01808.pdf; WoS; Scopus; NA; http://libdigitalcollections.ku.edu.tr/cdm/ref/collection/IR/id/8435Test

الإتاحة: https://doi.org/10.5152/kd.2019.33Test
http://libdigitalcollections.ku.edu.tr/cdm/ref/collection/IR/id/8435Test